An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 465-476

  Süssmuth, Sigurd D ^a   Haider, Salman ^b   Landwehrmeyer, G Bernhard ^a   Farmer, Ruth ^c   Frost, Chris ^c   Tripepi, Giovanna ^d   Andersen, Claus A ^d   Di Bacco, Marco ^d   Lamanna, Claudia ^d,e   Diodato, Enrica ^d   Massai, Luisa ^d   Diamanti, Daniela ^d   Mori, Elisa ^d   Magnoni, Letizia ^d   Dreyhaupt, Jens ^f   Schiefele, Karin ^f   Craufurd, David ^g,h   Saft, Carsten ⁱ   Rudzinska, Monika ^j   Ryglewicz, Danuta ^k   Orth, Michael ^a   Brzozy, Sebastian ^l   Baran, Anna ^l   Pollio, Giuseppe ^d   Andre, Ralph ^b   Tabrizi, Sarah J ^b   Darpo, Borje ^m,n   Westerberg, Goran ^d,o   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Siena Biotech SpA   (Italy)

^e European Huntington's Disease Network (EHDN)   (Italy)

^f UNIVERSITY OF ULM   (Germany)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ST JOSEF HOSPITAL   (Germany)

^j MEDICAL UNIVERSITY OF SILESIA   (Poland)

^k INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^l KCRSA   (Poland)

^m DANDERYD HOSPITAL   (Sweden)

ⁿ ICardiac Technologies   (United States)

^o La Crocina Pharmaceutical Consultants DI ^*  (Italy)

more..

Author keywords

Huntington's disease; pharmacodynamics; pharmacokinetics; selisistat; SirT1 inhibition

Indexed keywords

ALANINE AMINOTRANSFERASE; HUNTINGTIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; SELISISTAT; TUMOR NECROSIS FACTOR ALPHA; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; CARBAZOLE DERIVATIVE; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

ACCUMULATION RATIO; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CAG REPEAT; CAUCASIAN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; FEMALE; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; HYPERTRANSAMINASEMIA; IC50; IMMUNOMODULATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNIFIED HUNTINGTON DISEASE RATING SCALE; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; HUNTINGTON DISEASE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CARBAZOLES; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; SIRTUIN 1; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930012088     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12512     Document Type: Article

References (44)

1. Rubinsztein DC, Carmichael J,. Huntington's disease: molecular basis of neurodegeneration. Expert Rev Mol Med 2003; 5: 1-21.
2. van der Burg JM, Bjorkqvist M, Brundin P,. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009; 8: 765-774.
3. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, Neri C, Thompson LM, Marsh JL, Kazantsev AG,. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010; 107: 7927-7932.
4. Zuccato C, Valenza M, Cattaneo E,. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-981.
5. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio PM, Lauver MA, Choi SH, Silverman RB, Ferrante RJ, Hersch S, Kazantsev AG,. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep 2012; 2: 1492-1497.
6. Jeong H, Then F, Melia TJ Jr, Mazzulli JR, Cui L, Savas JN, Voisine C, Paganetti P, Tanese N, Hart AC, Yamamoto A, Krainc D,. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137: 60-72.
7. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, Chen J,. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 2011; 95: 373-395.
8. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL,. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008; 17: 3767-3775.
9. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JP, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, Thomas RJ, Kates M, Jones S, Navia MA, Saunders JO, DiStefano PS, Curtis R,. Discovery of indoles as potent and selective inhibitors of the deacetylase SirT1. J Med Chem 2005; 48: 8045-8054.
10. Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi SJ, Caricasole A, Landwehrmeyer B, Menalled L, Ramboz S, Luthi Carter R, Westerberg G, Marsh JL,. Sirtuin 1 inhibition alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014; 23: 2995-3007.
11. Westerberg G, Chiesa JA, Andersen CA, Diamanti D, Magnoni L, Pollio G, Darpo B, Zhou M,. Safety, pharmacokinetics, pharmacogenomics and QT concentration effect modelling of the SirT1 inhibitor selisistat in healthy volunteers. Br J Clin Pharmacol 2014. doi: 10.1111/bcp.12513.
12. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB,. Observing Huntington's disease: the European Huntington's disease network's REGISTRY. PLoS Curr 2010; 2: RRN1184.
13. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 1996; 11: 136-142.
14. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB Jr, Siemers E, Shoulson I,. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54: 452-458.
15. Craufurd D, Thompson JC, Snowden JS,. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 219-226.
16. Snaith RP, Constantopoulos AA, Jardine MY, McGuffin P,. A clinical scale for the self-assessment of irritability. Br J Psychiatry 1978; 132: 164-171.
17. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
18. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Wang C, Stout JC, Ross CA, Aylward E, Carlozzi NE, Queller S,. 'Frontal' behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 2010; 22: 196-207.
19. Arnett JA, Seth L,. Effects of physical layout in performance on the trail making test. Psychol Assess 1995; 7: 220-221.
20. Smith A,. The symbol-digit modalities test: a neuropsychologic test of learning and other cerebral disorders. In: Learning Disorders, ed., Helmuth J,. Seattle: Special Child Publications, 1968; 83-91.
21. MacLeod CM,. Half a century of research on the Stroop effect: an integrative review. Psychol Bull 1991; 109: 163-203.
22. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ,. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
23. Massai L, Petricca L, Magnoni L, Rovetini L, Haider S, Andre R, Tabrizi SJ, Sussmuth SD, Landwehrmeyer BG, Caricasole A, Pollio G, Bernocco S,. Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells. BMC Biochem 2013; 14: 34.
24. Frost C, Kenward MG, Fox NC,. Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency? Stat Med 2008; 27: 3717-3731.
25. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR,. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012; 11: 42-53.
26. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR,. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013; 12: 637-649.
27. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M,. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008; 79: 874-880.
28. Mestre T, Giuliano J, Handley OJ, Landwehrmeyer B, Sampaio C,. Enroll-HD: a global observational study enabling clinical research in Huntington's disease. J Huntington Dis 2013; 1: 34-35.
29. Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, Elmquist JK, Coppari R,. Brain SirT1: anatomical distribution and regulation by energy availability. J Neurosci 2008; 28: 9989-9996.
30. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I,. Evolutionarily conserved and nonconserved cellular localizations and functions of human SirT proteins. Mol Biol Cell 2005; 16: 4623-4635.
31. Chang HC, Guarente L,. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 2013; 153: 1448-1460.
32. Rao Y, Lu M, Ge F, Marsh DJ, Qian S, Wang AH, Picciotto MR, Gao XB,. Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus. J Neurosci 2008; 28: 9101-9110.
33. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P,. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008; 131: 2860-2869.
34. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K,. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SirT1. J Biol Chem 2010; 285: 8340-8351.
35. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenina T, Arbez N, Zhu S, Sommers K, Qian J, Zhang J, Mori S, Yang XW, Tamashiro KL, Aja S, Moran TH, Luthi-Carter R, Martin B, Maudsley S, Mattson MP, Cichewicz RH, Ross CA, Holtzman DM, Krainc D, Duan W,. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2011; 18: 153-158.
36. Pfister JA, Ma C, Morrison BE, D'Mello SR,. Opposing effects of sirtuins on neuronal survival: SirT1-mediated neuroprotection is independent of its deacetylase activity. PLoS ONE 2008; 3: e4090.
37. Seifert EL, Caron AZ, Morin K, Coulombe J, He XH, Jardine K, Dewar-Darch D, Boekelheide K, Harper ME, McBurney MW,. SirT1 catalytic activity is required for male fertility and metabolic homeostasis in mice. FASEB J 2012; 26: 555-566.
38. Kakefuda K, Fujita Y, Oyagi A, Hyakkoku K, Kojima T, Umemura K, Tsuruma K, Shimazawa M, Ito M, Nozawa Y, Hara H,. Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem Biophys Res Commun 2009; 387: 784-788.
39. Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, Kennedy C, Staines W, Rousseaux C, Mueller R, McBurney MW,. Sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 2008; 314: 3069-3074.
40. Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, Divekar R, McBurney MW, Braley-Mullen H, Zaghouani H, Fang D,. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009; 119: 3048-3058.
41. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P,. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 2011; 32: 258-270.
42. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P,. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130: 1759-1766.
43. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Moller T, Tabrizi SJ,. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008; 205: 1869-1877.
44. Giorgini F, Moller T, Kwan W, Zwilling D, Wacker JL, Hong S, Tsai LC, Cheah CS, Schwarcz R, Guidetti P, Muchowski PJ,. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 2008; 283: 7390-7400